Special Issue "Current Advances on Molecular & Clinical Oncology: Diagnosis, Management and Treatment of the Malignant Causative Genes"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Molecular Diagnostics".

Deadline for manuscript submissions: 31 December 2020.

Special Issue Editors

Dr. Sudip Chakraborty
Website
Guest Editor
Department of Computer Engineering, Modeling, Electronics and Systems (D.I.M.E.S.), Laboratory of Transport Phenomena and Biotechnology, University of Calabria, Cubo-42a, Via P. Bucci, 87036 Rende, Italy
Interests: Photocatalysis, Membrane reactor, Energy Conversion, Nanomaterials, Waste valorization, Inorganic Catalyst, Plasmonics.
Special Issues and Collections in MDPI journals
Dr. Gianpiero Aromolo

Guest Editor
Hospital of Cosenza and National Sanitary Medical Service of Italy, Via Rossini, 247, 87036 Rende (CS), Italy
Interests: pediatric oncology; haematology; pediatrics and neonatology; pediatrics cardiology; regenerative medicines; fetal cardiology; cosmetic surgery; pediatric asthma
Dr. Giampaolo De Luca

Guest Editor
Department of Pharmacy, University of Calabria, Rende, Italy
Interests: research and diagnostic of radio-immunology (dosage of GH, IGF-1 and other endocrine dependences); thalassemia; tumor; immune haematology; blood transfusion

Special Issue Information

Dear Colleagues,

Although laboratory and clinical cancer research need to be closely linked and observations should be at the basic level are often remain removed from medical applications. Not only that early diagnosis of clinical cancer and their treatment management are also not properly taken care of. In this special issue we will focus on current advancement on the cancer treatment not only by clinical means but also in genetic level by manipulating the causative genes. So we mostly focus on how we identify inherited/causative cancer, and current knowledge of the most frequent and clinically important forms of clinical cancers. The concept of identifying causative genes emerged from the recognized of its young onset in families more than 60 years ago. The last three decades has seen the causative genes for most of the high-penetrant cancer syndromes with Mendelian inheritance identified, and their genetic epidemiology is now being described. Its multidisciplinary approach allows us to keep up-to-date with developments in their own as well as related fields. Crucial to such descriptions is how to identify pathogenic variants of the causative genes, which are instrumental to demonstrate their associations with early stage of the disease. From the starting point of identifying the genes causing cancer with very high complexity of treatment challenges of is the aim of this special issue. Recent advancement of drug discovery developments in the field of small cancer molecule targeted agents have led to much interest in combining these clinical research with treatment management will also be covered in this special issue. Apart from different genetic variants with lower risk to develop cancer, and their interactions with other genes and environment, we will also welcome the contributions on this perceived future opportunities and challenges in the development of this exciting area of oncological research and study.

Prof. Dr. Sudip Chakraborty
Dr. Gianpiero Aromolo
Dr. Giampaolo De Luca
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.ynsqex.icu by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Molecularly targeted drugs
  • Genetic epidemiology
  • Prevention
  • Early detection
  • New technologies
  • Cancer biology
  • Clinical trials
  • Cancer causative genes

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Saliva Diagnosis as a Disease Predictor
J. Clin. Med. 2020, 9(2), 377; https://doi.org/10.3390/jcm9020377 - 30 Jan 2020
Abstract
Background: Saliva, the most readily available body fluid, is the product of genes which are in constant activity throughout life. Measurement of saliva can predict the onset of some diseases years before their accumulation in vulnerable tissues causes clinical signs to appear. The [...] Read more.
Background: Saliva, the most readily available body fluid, is the product of genes which are in constant activity throughout life. Measurement of saliva can predict the onset of some diseases years before their accumulation in vulnerable tissues causes clinical signs to appear. The purpose of this study was is to demonstrate current applications of saliva analysis and to predict and prevent disease progression. Methods: We measured levels of Abeta42, C-reactive proteins (CRPs), and tumornecrosis factors (TNFs) in saliva from both healthy and fatal diseased cases such as cancer, Alzheimer’s disease (AD), and coronary heart disease by ELISA-mediated techniques. We also immunostained human tissue sections with antibodies specific to these proteins to demonstrate the data are comparable. Results: We found all the proteins expressed constantly in saliva from healthy controls but increased in diseased cases. This was accompanied by data from immunohistochemistry. It was also found that these proteins wereexpressed in high amounts in some healthy controls, which reflects high risk for the onset of diseases such as AD and heart diseases.Conclusions: It is concluded that measuring changes in essential gene products in saliva can predict onset of fatal diseases and open the door to effective protection measures, thus preventing premature death. Full article
Show Figures

Figure 1

Back to TopTop 宝马游戏手机网站